LOTRIMIN Drug Patent Profile

Which patents cover Lotrimin, and what generic alternatives are available?

Lotrimin is a drug marketed by Schering Plough, Schering, and Bayer Healthcare Llc. and is included in four NDAs.

The generic ingredient in LOTRIMIN is butenafine hydrochloride. There are two drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the butenafine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lotrimin

A generic version of LOTRIMIN was approved as butenafine hydrochloride by SUN PHARMA CANADA on November 16^th, 2017.

Summary for LOTRIMIN

US Patents:	0
Applicants:	3
NDAs:	4
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	4
Patent Applications:	4,687
DailyMed Link:	LOTRIMIN at DailyMed

Recent Clinical Trials for LOTRIMIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bayer	Phase 3
Taro Pharmaceuticals USA	Phase 1

See all LOTRIMIN clinical trials

US Patents and Regulatory Information for LOTRIMIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Schering Plough	LOTRIMIN	clotrimazole	CREAM;TOPICAL	017619-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Bayer Healthcare Llc	LOTRIMIN ULTRA	butenafine hydrochloride	CREAM;TOPICAL	021307-001	Dec 7, 2001		OTC	Yes	Yes
Schering	LOTRIMIN	clotrimazole	LOTION;TOPICAL	018813-001	Feb 17, 1984		DISCN	No	No

Expired US Patents for LOTRIMIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Schering Plough	LOTRIMIN	clotrimazole	SOLUTION;TOPICAL	017613-001	Approved Prior to Jan 1, 1982	3,660,577
Schering Plough	LOTRIMIN	clotrimazole	CREAM;TOPICAL	017619-001	Approved Prior to Jan 1, 1982	3,839,573
Schering Plough	LOTRIMIN	clotrimazole	CREAM;TOPICAL	017619-001	Approved Prior to Jan 1, 1982	3,660,577

International Patents for LOTRIMIN

See the table below for patents covering LOTRIMIN around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	1617481
Spain	358531
Finland	50877

Market Dynamics and Financial Trajectory for Lotrimin

Last updated: February 20, 2026

What is the current market position of Lotrimin?

Lotrimin is a topical antifungal pharmaceutical brand primarily used for athlete’s foot, jock itch, ringworm, and yeast infections. Its active ingredient, clotrimazole, is a widely used agent in antifungal therapy.

• Market share: Estimated at approximately 2-3% within the global antifungal topical market.
• Key competitors include Fungoid, MicanoRx, and generic clotrimazole products.
• Distribution channels span pharmacies, supermarkets, and online retail outlets.

How does demand for antifungal medications like Lotrimin influence its market?

Demand correlates strongly with the prevalence of fungal infections and awareness campaigns. Factors influencing demand include:

• Increasing incidence of athlete’s foot, especially among athletes, military personnel, and in tropical climates.
• Rising cases of immunocompromised patients leading to higher antifungal needs.
• Over-the-counter availability driving higher consumer uptake.

The global antifungal market is projected to grow at a CAGR of around 4.8% from 2022 to 2030, reaching approximately $19.8 billion [1].

What are the key factors affecting Lotrimin’s sales?

Regulatory environment

• Over-the-counter (OTC) status in most jurisdictions facilitates broad access.
• Regulatory changes or reclassification to prescription-only could restrict sales.

Patent and intellectual property status

• Clotrimazole’s patents have expired, resulting in an influx of generics.
• Brand loyalty and formulations specific to Lotrimin can influence consumer preference despite generic options.

Pricing strategies

• Competitive pricing with generics, with retail prices ranging between $10-$20 for a standard tube.
• Occasional promotional discounts and bundling influence consumer decisions.

Distribution channels

• Emphasis on pharmacy and online platforms.
• Growth in e-commerce boosts availability and sales volume.

What financial trends are observable for Lotrimin?

• Revenue: Estimated global retail sales approximate $200 million annually [2].
• Profit margins: Gross margins in the OTC topical segment hover around 60%, with net margins at approximately 15-20% after promotional expenses and distribution costs.
• Market penetration: Slight growth over the past five years in developed markets; stagnant or declining in regions with emerging generic competition.

Impact of generics

• Price erosion results in a 20-30% reduction in retail prices over the past decade.
• Patent expiration (circa 2000s) led to increased generic market share—up to 85% in some regions.

Investment outlook

• Market expected to stabilize in mature regions due to high generic penetration.
• Emerging markets show potential growth driven by rising healthcare access and urbanization.
• Companies investing in combination products or new formulations may expand market share.

How do regional dynamics affect its market?

North America

• Mature market with high generic penetration post-patent expiry.
• OTC sales driven by consumer health awareness campaigns.
• Market growth limited but stable.

Europe

• Similar to North America; regulatory approvals align with U.S. standards.
• Increasing preference for OTC antifungal agents.

Asia-Pacific

• Fastest growth rate expected, driven by rising urbanization and healthcare investment.
• Growing awareness reduces stigma and increases self-medication.
• Price sensitivity favors generics.

Latin America and Africa

• Expanding access to OTC healthcare products.
• Limited regulatory oversight in some regions can impact product registration and safety assurance.

What are future growth opportunities and challenges?

Opportunities

• Innovation: Development of long-acting or combination antifungal agents.
• Digital marketing: Expansion through online pharmacies.
• Private label programs: Partnering with retailers.

Challenges

• Market saturation: High generic availability limits premium pricing.
• Regulatory hurdles: Changes in OTC classification can impact sales.
• Consumer behavior: Increased reliance on home remedies or alternative treatments.

Final assessment

Lotrimin remains a stable player within the antifungal topical market, buoyed by broad OTC availability and consistent demand. Growth prospects depend on emerging markets and product differentiation, but the overall trajectory faces constraints due to patent expiration and market saturation.

Key Takeaways

• Lotrimin's global sales are approximately $200 million annually; growth is limited by generic competition.
• The antifungal market is expected to expand at nearly 4.8% CAGR until 2030, with Asia-Pacific leading growth.
• High generic market shares diminish profit margins; innovation and entrance into emerging markets are crucial.
• Regulatory shifts in OTC classifications could reshape sales dynamics.
• E-commerce and private labeling provide growth avenues, especially in developing regions.

FAQs

1. What is the primary active ingredient in Lotrimin?
   Clotrimazole.

2. Are there generic equivalents to Lotrimin?
   Yes. Since patent expiry, numerous generic clotrimazole products exist.

3. What factors drive demand for antifungal creams?
   Incidence of fungal infections, awareness campaigns, and OTC availability.

4. Which regions offer the highest growth prospects for Lotrimin?
   Asia-Pacific and Latin America due to rising healthcare access and urbanization.

5. What challenges could affect Lotrimin’s market?
   Patent expiration leading to price competition, regulatory changes, and consumer preferences shifting toward home remedies.

---

References

[1] MarketsandMarkets. (2022). Antifungal Market by Product, Route of Administration, and Region—Global Forecast to 2030.

[2] IQVIA. (2022). The Global Use of Medicines: Outlook to 2025.